• Can understanding a subject’s motivation for trial participation help recruiting?
• How many sites do you need for your trial?
• Can anticipating the number of dropouts help determine sample size?
• Can the SD of glaucoma medications help you size your trial?
• What's the recommended washout period for glaucoma medications?
• Do you know the risk factors for subject withdrawals?
• How many IOP measurements are needed at each timepoint?
• Subjective IOP values – can subjects guess their IOP?
• Are IOPs in early phase studies predictive?
• Symptom reporting – should you elicit?
• Do you know the cost of Serious Adverse Event reporting?

Each month we provide a review of the worldwide, peer-reviewed ophthalmic literature. Download a sample copy or sign up for monthly delivery to your electronic mailbox.

• Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol 2010;4:1355-9.

• Lee PW, Doyle A, Stewart JA, Kristoffersen CJ, Stewart WC. Meta-analysis of timolol on the diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol 2010;20:1035-41.

• Stewart WC, Sharpe ED, Kristoffersen CJ, Nelson LA, Stewart JA. Association of strength of religious adherence to attitudes regarding glaucoma or ocular hypertension. Ophthalmic Res 2011:45:53-6.

• Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-398.

• Stewart WC, Adams MP, Stewart JA, Nelson LA. Survey of practice-related stress among United States and European ophthalmologists. Graefes Arch Clin Exp Ophthalmol 2011;249:1277-80.

• Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC.  Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.  J Glaucoma 2012;21:55-59.